Detection of Patient HIV-1 Drug Resistance Mutations in Russia's Northwestern Federal District in Patients with Treatment Failure

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 Aug 26

PMID 36010172

Authors

Alexander N Shchemelev

Yulia V Ostankova

Elena B Zueva

Alexander V Semenov

Areg A Totolian

Affiliations

Soon will be listed here.

Abstract

Highly active antiretroviral therapy (HAART) is currently a combination of three (less frequently four) antiretroviral drugs; these target pathways involved in various stages of HIV replication in the body. Treatment failure is a problem facing doctors and patients using HAART. The most common cause of therapeutic failure is the development of HIV drug resistance. The emergence of resistance is associated with processes involving mutation occurring in the viral genome under the influence of evolutionary factors. Sequencing reactions were performed using the AmpliSens HIV Resist-Seq. Assembly of consensus sequences from fragments obtained during sequencing was carried out using Unipro UGENE softwar. Isolate genotyping was performed using the MEGA-X software with the Neighbor-joining algorithm. According to the analysis, 72.05% of patients had at least one significant mutation associated with drug resistance for the corresponding viral subtype. HIV-1 A6 remains the predominant HIV-1 genetic variant in Russia's Northwestern Federal District. Among samples with drug resistance mutations, in all cases, mutations associated with pharmacological resistance to two or three drug groups were found. Given the high incidence of resistance mutations in patients on ineffective ART, surveillance of HIV-1 drug resistance, in both ART-receiving and ART-naive individuals, appears necessary. A lack of vigilance and control measures may lead to the spread of primary ART-resistant HIV strains.

Citing Articles

Prevalence of HIV and Viral Hepatitis Markers among Healthcare Workers in the Republic of Guinea.

Ostankova Y, Shchemelev A, Boumbaly S, Balde T, Zueva E, Valutite D Diagnostics (Basel). 2023; 13(3).

PMID: 36766482 PMC: 9914033. DOI: 10.3390/diagnostics13030378.

Reconstructing the Temporal Origin and the Transmission Dynamics of the HIV Subtype B Epidemic in St. Petersburg, Russia.

Siljic M, Cirkovic V, Jovanovic L, Antonova A, Lebedev A, Ozhmegova E Viruses. 2022; 14(12).

PMID: 36560752 PMC: 9783597. DOI: 10.3390/v14122748.

References

Golosova O, Henderson R, Vaskin Y, Gabrielian A, Grekhov G, Nagarajan V . Unipro UGENE NGS pipelines and components for variant calling, RNA-seq and ChIP-seq data analyses. PeerJ. 2014; 2:e644. PMC: 4226638. DOI: 10.7717/peerj.644. View

Hu Z, Giguel F, Hatano H, Reid P, Lu J, Kuritzkes D . Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol. 2006; 80(14):7020-7. PMC: 1489059. DOI: 10.1128/JVI.02747-05. View

Okonechnikov K, Golosova O, Fursov M . Unipro UGENE: a unified bioinformatics toolkit. Bioinformatics. 2012; 28(8):1166-7. DOI: 10.1093/bioinformatics/bts091. View

Kolomeets A, Varghese V, Lemey P, Bobkova M, Shafer R . A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. AIDS. 2014; 28(17):F1-8. PMC: 4393743. DOI: 10.1097/QAD.0000000000000485. View

Weiss R . How does HIV cause AIDS?. Science. 1993; 260(5112):1273-9. DOI: 10.1126/science.8493571. View

Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S . Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999; 340(21):1605-13. DOI: 10.1056/NEJM199905273402101. View

Kotova V, Trotsenko O, Balakhontseva L, Bazykina E . [Molecular genetic characteristics of HIV-1 variants isolated in the subjects of the Russian Far East.]. Vopr Virusol. 2019; 64(2):79-89. DOI: 10.18821/0507-4088-2019-64-2-79-89. View

Mamatkulov A, Kazakova E, Ibadullaeva N, Joldasova E, Bayjanov A, Musabaev E . Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan. AIDS Res Hum Retroviruses. 2020; 37(1):38-43. DOI: 10.1089/AID.2020.0096. View

Taylor B, Sobieszczyk M, McCutchan F, Hammer S . The challenge of HIV-1 subtype diversity. N Engl J Med. 2008; 358(15):1590-602. PMC: 2614444. DOI: 10.1056/NEJMra0706737. View

10.

Bbosa N, Kaleebu P, Ssemwanga D . HIV subtype diversity worldwide. Curr Opin HIV AIDS. 2019; 14(3):153-160. DOI: 10.1097/COH.0000000000000534. View

11.

Rhee S, Gonzales M, Kantor R, Betts B, Ravela J, Shafer R . Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003; 31(1):298-303. PMC: 165547. DOI: 10.1093/nar/gkg100. View

12.

Sacktor N, Nakasujja N, Skolasky R, Rezapour M, Robertson K, Musisi S . HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis. 2009; 49(5):780-6. PMC: 2941149. DOI: 10.1086/605284. View

13.

Ekici H, Rao S, Sonnerborg A, Ramprasad V, Gupta R, Neogi U . Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries. J Antimicrob Chemother. 2014; 69(12):3349-55. DOI: 10.1093/jac/dku278. View

14.

Troyer R, Collins K, Abraha A, Fraundorf E, Moore D, Krizan R . Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol. 2005; 79(14):9006-18. PMC: 1168764. DOI: 10.1128/JVI.79.14.9006-9018.2005. View

15.

Chen M, Zhu Q, Xing H, Chen H, Jin X, Dong L . The characteristics of pretreatment HIV-1 drug resistance in western Yunnan, China. Epidemiol Infect. 2020; 148:e102. PMC: 7315466. DOI: 10.1017/S095026882000093X. View

16.

Bobkov A, Kazennova E, Selimova L, Khanina T, Ryabov G, Bobkova M . Temporal trends in the HIV-1 epidemic in Russia: predominance of subtype A. J Med Virol. 2004; 74(2):191-6. DOI: 10.1002/jmv.20177. View

17.

Hellinger F, Encinosa W . Antiretroviral therapy and health care utilization: a study of privately insured men and women with HIV disease. Health Serv Res. 2004; 39(4 Pt 1):949-67. PMC: 1361046. DOI: 10.1111/j.1475-6773.2004.00266.x. View

18.

Rose R, Golosova O, Sukhomlinov D, Tiunov A, Prosperi M . Flexible design of multiple metagenomics classification pipelines with UGENE. Bioinformatics. 2018; 35(11):1963-1965. DOI: 10.1093/bioinformatics/bty901. View

19.

Flor-Parra F, Perez-Pulido A, Pachon J, Perez-Romero P . The HIV type 1 protease L10I minor mutation decreases replication capacity and confers resistance to protease inhibitors. AIDS Res Hum Retroviruses. 2010; 27(1):65-70. DOI: 10.1089/aid.2010.0072. View

20.

Cheung K, Peng Q, He L, Cai K, Jiang Q, Zhou B . Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY® System. PLoS One. 2016; 11(4):e0153641. PMC: 4836728. DOI: 10.1371/journal.pone.0153641. View